#USA #Veeva Systems #biotechnology #Pleasanton #BioMarin

Strategic Partnership Between Veeva Systems and BioMarin

On January 8, 2026, Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) unveiled their long-term partnership, solidifying a relationship that has developed over many years. This alliance is designed to enhance BioMarin’s capabilities in efficiently developing and commercializing innovative therapies, leveraging Veeva's integrated software, data, and consulting services.

Objectives of the Partnership

The collaboration aims to significantly ramp up BioMarin's operational efficiency and agility in bringing their innovative medicines to market. By utilizing Veeva's cloud-based solutions, BioMarin intends to optimize its interactions with healthcare professionals and improve patient experiences, setting a foundation for increasing productivity and effectiveness in drug development.

Alexander Hardy, the CEO of BioMarin, expressed his enthusiasm regarding this collaboration, stating, "This strategic alliance represents a major advancement in our digital evolution. We are excited about the opportunity to combine our scientific expertise with Veeva's technological leadership, which we believe will allow us to bring our innovative medicines to patients around the world more quickly."

Peter Gassner, CEO of Veeva, echoed this sentiment, emphasizing the shared values that guide their collaboration. "Our partnership with BioMarin has always been driven by common goals—product excellence, value creation, and customer success. I look forward to continuing support for BioMarin in developing crucial new therapies and reaching more patients globally."

About BioMarin

Founded in 1997 and headquartered in San Rafael, California, BioMarin is a global leader in biotechnology for rare diseases, focusing on developing medications for genetically defined conditions. The firm boasts eight commercially available therapies and robust clinical and preclinical product pipelines. By pursuing a unique approach to drug discovery and development, BioMarin intends to unlock the full potential of genetic science through groundbreaking medicines that make a significant impact on patient lives. More information can be found on their website: www.biomarin.com.

About Veeva Systems

Veeva provides the cloud-based sector for life sciences through its business software, data, and consulting services. Committed to innovation, product excellence, and client success, Veeva serves over 1,500 customers, spanning from the largest global biopharmaceutical firms to emerging biotech companies. As a Public Benefit Corporation, Veeva is devoted to balancing the interests of its stakeholders, including customers, employees, shareholders, and the industries it serves. For more details, visit veeva.com.

Future Implications

The strategic partnership between Veeva and BioMarin is poised to revolutionize how therapies for rare diseases are developed and brought to market. By merging BioMarin’s scientific expertise with Veeva’s leading technology, the two companies are well-positioned to set new standards in the pharmaceutical industry, focused on efficiency and patient-centric solutions. As this partnership progresses, both companies' commitment to innovation and improving patient outcomes will be critical in navigating the complex landscape of drug development. Investors and stakeholders will surely watch this collaboration closely, as its outcomes could redefine success metrics in biotechnology and pharmaceuticals.